Small molecule · developed by Xenon Pharmaceuticals
Azetukalner (XEN1101) is an orally administered agent given as a 20 mg capsule once daily in clinical studies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07217860 | Phase 3 | Bipolar Depression | Active not recruiting | XENE |
| NCT05667142 | Phase 3 | Primary Generalized Tonic-Clonic Seizures | Recruiting | XENE |
| NCT05376150 | Phase 2 | Major Depressive Disorder | Completed | XENE |
| NCT04952467 | Phase 1 | Healthy Volunteers | Completed | XENE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bipolar DepressionBipolar DisorderBipolar I DisorderBipolar II DisorderPrimary Generalized Tonic-Clonic SeizuresHealthy VolunteersMajor Depressive Disorder
Updated Nov 15, 2026. Something wrong or missing? Report it on the XENE page.
See XENE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XENE catalysts and pipeline →